Prescient Therapeutics Limited · ASX:PTX
Prescient Therapeutics — Shareholder Meeting (October 2025)
20 slides from Prescient Therapeutics's shareholder meeting presentation, Oct 14, 2025
Slide 1: Annual General Meeting: Chair's Address & CEO Presentation
Annual General Meeting Chair's Address & CEO Presentation 14 October 2025 Dr James Campbell, Chair Good morning, and welcome to Prescient Therapeutics' Annual General Meeting for 2025. It has been a transformational year for our company, marked by significant clinical progress, For personal use only
Slide 2: Chair's Address: Leadership, Partnerships and Outlook
and August—raising nearly $10 million to support PTX-100's Phase 2a development. The strong participation in both the SPP and placement reflects shareholder confidence in our strategy and excitement for what lies ahead. Leadership and Team Building This year's leadership transitions have positioned
Slide 3: Acknowledgments and About Prescient Therapeutics
The fundamentals are in place: compelling clinical data, regulatory validation, financial resources, and an experienced team. We remain committed to creating long-term shareholder value while maintaining the highest standards of governance and execution. Acknowledgments On behalf of the Board, I tha
Slide 4: About Prescient: Targeted Therapy and Cell Therapy Platforms
relapsed or refractory (r/r) mycosis fungoides, the most common subtype of CTCL. A Phase 2 study in Cutaneous T cell lymphoma (CTCL) is recruiting globally and expects to enrol up to 40 patients in the phase 2a part of the trial. Cell Therapy Platforms CellPryme-M: Prescient's novel, ready-for-the-c
Slide 5: Forward-looking statements
or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate
Slide 6: AGM CEO Presentation
For personal use only AGM CEO Presentation October 2025 ASX: PTX ptxtherapeutics.com
Slide 7: Disclaimer and Safe Harbour
Disclaimer and Safe Harbour For personal use only Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts
Slide 8: Executive Summary
Executive Summary PTX-100 First in Class Targeted Therapy Disrupting the RAS Pathway For personal use only First in class RAS disruptor through inhibition of geranylgeranyl Unique and First transferase 1 preventing prenylation of RAS super family GTPases Phase 2a initiated in refractory/relapsed Cut
Slide 9: Company Snapshot
Company Snapshot For personal use only KEY METRICS ASX Ticker PTX Total Issued Capital 1,051 M shares Share Price1 A$0.043 Market A$45 M Capitalisation1 Cash Position2 A$12.32M Top 20 Own 19.5% 1. As at 10 October 2025 2. As at 30 September 2025 (4C)
Slide 10: Milestone Review (CY)
Milestone Review (CY) Achieved Milestones Provided Focus for PTX-100 Phase 2a Initiation For personal use only
Slide 11: Board and Management Team
Board and Management Team Experienced team of drug developers and deal makers with track For personal use only record in blood cancers Management Team Experienced gained in global companies Dr Rebecca Tunstall COO Board of Directors Melanie Farris Non-Executive Director
Slide 12: Targeted RAS therapy for cancers of unmet need
Targeted RAS therapy for cancers of unmet need Potential application to 22% of all cancers For personal use only Our Lead Asset– PTX-100 ● Addressing cancer : T-Cell Lymphoma (TCL) and identifying other indications ● Early results beyond benchmarks and existing drugs ● FDA support though designation
Slide 13: Phase 1b Sub-analysis of CTCL Patient Cohort
Phase 1b Sub-analysis of CTCL Patient Cohort For personal use only Response Rates, Safety and Duration are Key Drivers PTX-100 PTX-100 Benchmark1 Lymphir2,3 (Phase 1B)4 (CTCL only)5 Response Rate 30% 36% 45% 43% Clinical Benefit 45% NA 64% 100% Rate Duration of 9-13 months CTCL 6.5 months 10.7 month
Slide 14: Progressing PTX-100 Through Phase 2
Progressing PTX-100 Through Phase 2 with FDA IND acceptance For personal use only 500mg/m2 x 20 pts Dose r/r CTCL Randomization confirmation 2nd Line Phase 2a Dose Phase 2b Enrolment Dose Optimisation Optimisation Efficacy X40 patients Committee X 75 pts (pts) 1000mg/m2 x 20 pts Multicenter clinical
Slide 15: PTX-100 (CTCL) – Status Quo
PTX-100 (CTCL) – Status Quo For personal use only Clinical Trial Basic Preclinical On Phase I Clinical PhaseTrial II Phase III MA Research Studies Market Safety Dose finding Confirmatory Studies and efficacy efficacy and studies safety studies PTX-100 (CTCL) 2023 2024 Orphan Investigational Engageme
Slide 16: Potential for a Shortened Registration Pathway
Potential for a Shortened Registration Pathway For personal use only Years & Clinical Trial $$$ saved Basic Basic Preclinical Preclinical Phase Phase On On Researc Phase I Clinical Phase Phase Trial IIII MA MA Research Studies Studies I III Market Market h Safety Dose finding Studies and efficacy st
Slide 17: PTX-100 First in Class Targeted Therapy
PTX-100 First in Class Targeted Therapy Identifying PTX-100 RAS sensitive tumours to expand indications For personal use only ● Potential application to 22% of cancers ● First in class enzyme inhibitor ● PTX-100 (TCL) = proof of concept ● Opportunity for significantly larger cancer markets
Slide 18: Approaching Milestones (CY)
Approaching Milestones (CY) For personal use only Implementation Will Drive Value
Slide 19: Executive Summary
Executive Summary PTX-100 First in Class Targeted Therapy Disrupting the RAS Pathway For personal use only First in class RAS disruptor through inhibition of geranylgeranyl Unique and First transferase 1 preventing prenylation of RAS super family GTPases Phase 2a initiated in refractory/relapsed Cut
Slide 20: Thank you
For personal use only Thank you ASX: PTX ptxtherapeutics.com
Prescient Therapeutics — Shareholder Meeting (October 2025) on 6ix